Post-treatment, a significant increase in both CD3+ T cells and CD8+ T cells was observed, suggesting that camrelizumab plus apatinib and SOX could recruit T cells and remodel a more ‘inflamed’ TME in AFP-G/GEJ adenocarcinoma (supplementary Fig. 14). Here, CD8A is linked to adenocarcinoma.